PDCD1 and neoplasm: Using single-cell RNA sequencing and mass cytometric profiling, we profile tumor-infiltrating immune cells from transplant and primary tumors before and after RT and anti-PD-1 immunotherapy, which reveals marked differences in their immune landscapes.